Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | CSF1R | P07333 | 18/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.51 |
| ▸ | KIT | P10721 | 7/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.49 |
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736768 | 1.00 | KDR (0.52) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL30086949 | 0.87 | CSF1R (0.54) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL5339144 | 0.87 | FYN (0.48) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL2416158 | 0.87 | CSF1R (0.54) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL16029060 | 0.87 | CSF1R (0.51) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL14447156 | 0.86 | FYN (0.58) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL2410569 | 0.86 | KDM4E (0.47) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL23900592 | 0.86 | CSF1R (0.51) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL29736898 | 0.85 | CSF1R (0.50) | KDRCSF1RPDGFRAKITFLT3 | |
| SCHEMBL23888616 | 0.85 | KDR (0.54) | KDRCSF1RPDGFRAKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-06-08 | — | — | US | disclosed |
| WO-2021197276-A1 | Amide compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| US-9902709-B2 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-9902709-B2 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-9902709-B2 | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | PEKING UNIVERSITY FOUNDER GROUP CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| EP-3130588-A1 | POLYSUBSTITUTED PYRIDINE COMPOUND, PREPARATION METHOD, USE AND PHARMACEUTICAL COMPOSITION | Peking University Founder Group Co., Ltd (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029404-A1 | POLYSUBSTITUTED PYRIDINE COMPOUND, PREPARATION METHOD, USE AND PHARMACEUTICAL COMPOSITION | NEW FOUNDER HOLDINGS DEVELOPMENT LIMITED LIABILITY COMPANY (CN) | 2017-02-02 | — | — | US | disclosed |
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2146716-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008131227-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2007076474-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155746-A1 | NOVEL SUBSTITUTED PYRIDINYLOXY AND PYRIMIDINYLOXY AMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 508/4885CSF1R 1317/4885PDGFRA 233/4885 |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | KDR 2434/4885CSF1R 1244/4885PDGFRA 618/4885 |
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, ASS1, NAT1 | KDR 4535/4885CSF1R 2941/4885PDGFRA 3533/4885 |
| US-20170029404-A1 | POLYSUBSTITUTED PYRIDINE COMPOUND, PREPARATION METHOD, USE AND PHARMACEUTICAL COMPOSITION | PIK3CA, PDXK, DMPK | KDR 759/4885CSF1R 2428/4885PDGFRA 930/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | KDR 239/4885CSF1R 197/4885PDGFRA 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.